Abstract
Nasal cavity and paranasal sinus cancers comprise about 1% of all malignancies, and 5% of head and neck malignancy. Squamous cell carcinoma comprises more than half of nasal cavity cancers. Treatment is determined by considering tumor size, location, staging, age, general condition, purpose of treatment, etc. Conventional therapy includes surgery, radiotherapy, and chemotherapy; however, for the locally advanced, recurrent, or metastatic cancer after conventional therapy, immunotherapy or targeted therapy are taken into consideration. Target therapy attacks specific cancer cells directly, such as cancer cells with certain gene mutation, whereas immunotherapy attacks cancer cells indirectly, stimulating our own immune system, such as T-cell activity. Histologically poorly differentiated carcinomas are treated with surgery, radiotherapy, and sometimes chemotherapy, but 5-year survival rate is low due to frequent recurrence. Here, we present a case of successful targeted therapy applied to recurrent nasal cavity cancer after serial application of conventional therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Korean Journal of Otorhinolaryngology-Head and Neck Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.